Back to Peptides
LongevityLow Risk

Livagen

Also known as: Lys-Glu-Asp-Glu, Liver bioregulator, Khavinson liver peptide

Half-life:
Unknown

Administration Routes

subcutaneous injectionintramuscular injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

A Khavinson liver bioregulator that promotes hepatocyte regeneration and liver function restoration. Also activates immune cell chromatin, aiding immune function in immunocompromised states.

Primary Research Areas

  • liver cell regeneration
  • hepatoprotection
  • immune restoration via liver
  • chromatin activation

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Russian liver peptide bioregulator (Lys-Glu-Asp-Gly) from Khavinson Institute. Studied for aging and hepatic function. No FDA approval, no NDA or IND. Research chemical in US.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Livagen

No active associated providers listed yet.